Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3 USD | -1.32% | -1.64% | -27.54% |
May. 08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on Relmada Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Relmada Therapeutics, Inc.
SVB Securities LLC | |
Oppenheimer | |
Guggenheim | |
Goldman Sachs | |
Truist Securities | |
SVB Leerink | |
Mizuho Securities |
EPS Revisions
- Stock Market
- Equities
- RLMD Stock
- Consensus Relmada Therapeutics, Inc.